Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled trial of sitafloxacin fumarate injection for adult community-acquired bacterial pneumonia
CTR20241745Phase 3Completed
- Sponsor
- Nanjing Youke Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sitafloxacin in community acquired pneumonia (CAP), sponsored by Nanjing Youke Pharmaceutical. Started May 2024; status: completed.
02
Drugs
sitafloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on CTR20241745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241745.